Brief: Sedana Medical U.S. Studies Meet First Key Secondary Endpoint

Sedana Medical AB (publ)

10/06/2025 07:08

June 10 (Reuters) - Sedana Medical AB (publ) SEDANA.ST:

US STUDIES MEET FIRST KEY SECONDARY ENDPOINT

SIGNIFICANT OPIOID DOSE REDUCTION FOUND IN ISOFLURANE GROUP

NO NEW SAFETY SIGNALS FOR ISOFLURANE IN SEDANA MEDICAL STUDIES

Source text: ID:nMFN6qNyg3

Further company coverage: SEDANA.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))